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Abstract: Polycystic ovary syndrome (PCOS) represents the most common endocrine 
dysfunction in fertile women and it is considered a heterogeneous and multifaceted disorder, 
with multiple reproductive and metabolic phenotypes which differently affect the early- and 
long-term syndrome’s risks. Women with PCOS present an adverse reproductive profile, 
including a high risk of pregnancy-induced hypertension, preeclampsia, and gestational diabetes 
mellitus. Patients with PCOS present not only a higher prevalence of classic cardiovascular 
risk factors, such as hypertension, dyslipidemia, and type-2 diabetes mellitus, but also of non-
classic cardiovascular risk factors, including mood disorders, such as depression and anxiety. 
Moreover, at the moment, clinical data on cardiovascular morbidity and mortality in women 
with PCOS are controversial. Finally, women with PCOS show an increased risk of endome-
trial cancer compared to non-PCOS healthy women, particularly during premenopausal period. 
Currently, we are unable to clarify if the increased PCOS early- and long-term risks are totally 
due to PCOS per se or mostly due to obesity, in particular visceral obesity, that characterized 
the majority of PCOS patients. In any case, the main endocrine and gynecological scientific 
societies agree to consider women with PCOS at increased risk of obstetric, cardiometabolic, 
oncology, and psychological complications throughout life, and it is recommended that these 
women be accurately assessed with periodic follow-up.
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Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disease in women, 
characterized by heterogeneous presentation of hyperandrogenism, ovulatory dysfunc-
tion, and polycystic ovarian morphology (PCOM). Despite PCOS being considered the 
most common female endocrinopathy during the reproductive life,1,2 the prevalence 
estimate greatly varies, ranging from 6% to 10%1,3,4 depending on the diagnostic criteria 
used5 and on the multiple faces with which this complex syndrome occurs.
The first recognition of the disease goes back to 1935 with Stein and Leventhal 
description,6 since then many scientific societies and workshop groups developed 
different diagnostic criteria, with the aim to provide a more inclusive definition of 
the syndrome. The National Institute Health (NIH) diagnostic criteria were based 
on the results of a survey among experts who considered a woman with PCOS if 
she presented with the combination of chronic oligo- or anovulation and clinical or 
biochemical signs of hyperandrogenism, with the exclusion of other related endocrine 
disorders.7 In 2003, the European Society of Human Reproduction and Embryology 
(ESHRE)/American Society of Reproductive Medicine (ASRM)-Sponsored PCOS 
Consensus Workshop Group suggested, after an international meeting held in Rot-
terdam, the addition of a third criteria, ie, the presence of PCOM, establishing the 
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PCOS diagnosis by the presence of at least two of these 
three criteria (chronic anovulation, hyperandrogenism, 
and PCOM on ultrasonography).8 Over the years, in the 
light of the ongoing clinical and metabolic relevance of the 
hyperandrogenism,9–11 the Androgen Excess and PCOS (AE-
PCOS) Society postulated the androgen excess as a central 
feature of the disease and PCOS should be defined by the 
presence of hyperandrogenism (clinical and/or biochemical) 
in combination with ovarian dysfunction (oligoanovulation 
and/or PCOM), with the exclusion of related disorders from 
other causes.12 That criteria were based on the best scientific 
evidences available on the issue. In 2011, the Amsterdam 
ESHRE/ASRM-Sponsored Third PCOS Consensus Work-
shop Group13 identified different phenotypes, according to 
the different criteria’s combinations and separated the most 
classic phenotype, characterized by hyperandrogenism and 
chronic anovulation, from those characterized by ovarian 
dysfunction and PCOM. On December 2012, the NIH 
Evidence-Based Methodology Workshop on PCOS14 con-
firmed and recommended to maintain the broad diagnostic 
Rotterdam criteria along with the identification of the spe-
cific PCOS phenotypes for each single patient, especially 
for their different potential cardiometabolic implications; 
indeed the identification of specific phenotypes in women 
with PCOS seems to be justified from the metabolic point 
of view.15 More recently, in the Practice Guidelines of the 
Endocrine Society, the use of the Rotterdam criteria for 
PCOS diagnosis was confirmed,16 even if the characteriza-
tion of the specific phenotype at diagnosis was not consid-
ered clinically needed. This crucial point is still under debate 
in the scientific community.17
Several articles have been published on the short- and 
long-term effects of PCOS on the women’s health due to an 
increased incidence of early complications such as a worsen-
ing of fertility and obstetric outcomes and to an increased 
rate of late complications as well as enhanced cardiovascular, 
metabolic, and oncology risks. It is very difficult to accu-
rately define the precise extent of these complications, due 
to the heterogeneous nature of the syndrome, the unclear 
pathogenetic mechanisms, and the presence of confounding 
factors, such as obesity. Moreover, the PCOS phenotypes in 
women change across the life span;18 therefore, the changes 
in ovarian function and in the metabolic regulation could 
modify the disease’s expression and that may play a role in 
the morbidity of the syndrome during the late reproductive 
age and menopause.
In line with these considerations, the current review 
was aimed at summarizing the current knowledge and 
perspectives about the short- and long-term complications 
of PCOS on the women’s health and longevity, considering 
PCOS not only as a reproductive age disorder but as a long-
life syndrome.
Early-term complication
Infertility
Infertility was one of the main symptoms originally attributed 
to the PCOS according to the first description.6 Subsequent 
epidemiologic evidences suggested that PCOS is the most 
common cause of ovulatory disorder and oligoanovulation is 
related with increased risk for infertility.19 In a large popula-
tion of 1,741 women affected by PCOS, primary infertility 
was reported in 50% of women, while secondary infertility 
was reported in 25% of women.20
Several PCOS comorbidities seemed to contribute to 
infertility. In particular, insulin resistance (IR)21 and obesity22 
were independently related to an increased risk of abortion 
and to reduced pregnancy and live-birth rates. Endometrial 
abnormalities were also reported in PCOS women,23,24 affect-
ing potentially the implantation. Finally, ovarian alterations 
at several levels were described, ie, ovarian/follicular/corpus 
luteum vascularity,25 follicular fluid environment,26,27 and 
subsequent oocytes competence26 and quality.28
Notwithstanding that theoretical reproductive abnormali-
ties related to the syndrome, the available studies based on 
modern PCOS diagnostic criteria and with sample sizes suf-
ficiently large seemed to report conflicting results.29–32
The typical PCOM appeared to diminish with increasing 
age.33 Similarly, menstrual cycles become normalized with 
increasing age in PCOS women.29,34 Finally, a recent study 
demonstrated that the reproductive outcome of women with 
a previous diagnosis of PCOS was similar to that of a non-
PCOS population.32 In particular, ovarian reserve seemed to 
be better preserved in PCOS women,32 resulting in a larger 
duration of the reproductive window during aging.35 The live-
birth rate and the rate of miscarriages were similar in PCOS 
patients and control women, and in more than two-thirds 
of the PCOS women, pregnancy occurred spontaneously.32 
Similar pregnancy and live-birth rates between PCOS and 
control women were also reported after conventional in vitro 
fertilization (IVF) by a meta-analysis.36
International documents13 highlighted the lack of clear 
data on the risk of miscarriage in women with PCOS, and 
that PCOS should be not considered per se a risk factor for 
miscarriage. The most recent guidelines of the Endocrine 
Society-appointed Task Force of Experts16 suggested that 
PCOS is a risk factor for infertility only in the presence of 
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oligoanovulation; thus they recommended screening ovula-
tory status using menstrual history in all women with PCOS 
seeking fertility. 
Obstetric complications
PCOS has historically been defined as a syndrome related 
to ovulatory infertility. Today, especially with the introduc-
tion of the new diagnostic criteria,37 the focus has shifted to 
reproductive problems, including also the obstetrics com-
plications. Moreover, the obstetric risk may be exacerbated 
by comorbidities, such as obesity and/or IR typical of the 
syndrome.
From a pathogenetic point of view, the increased inci-
dence of pregnancy complications in women with PCOS can 
be the result of several factors, such as PCOS features, infer-
tility treatments, multiple pregnancies, obesity, IR and meta-
bolic dysfunction, inflammation, and placental alterations.38 
In practice, several data uncontrolled for body mass index 
(BMI), including mostly retrospective or prospective stud-
ies with relatively small samples, have been published on 
maternal, neonatal, and obstetric complications in women 
with PCOS.38 These data were described and analyzed in 
three systematic reviews with meta-analysis.39–41
It is still debated whether women with PCOS have an 
increased risk of miscarriage compared to women without 
PCOS. In the PCOS consensus 2012, miscarriage rates 
are suggested to be comparable between women with and 
without PCOS, although data show conflicting results.13 
A meta-analysis of studies concerning women with and 
without PCOS undergoing IVF demonstrated no difference 
in miscarriage rates.36 This result was confirmed in a recent 
large cohort study.42 Moreover, most women with PCOS 
become pregnant by using ovulation induction medications 
that can modify the risk of miscarriage compared to women 
with natural conception.38
All meta-analyses on pregnancy complications39–41 were 
in agreement in reporting an increased risk of pregnancy- 
induced hypertension or preeclampsia in women with PCOS 
of at least threefold. That data, obtained from retrospec-
tive studies, have been recently confirmed by a prospec-
tive study.43 Specifically, the risk of pregnancy-induced 
hypertension and preeclampsia resulted of 12.7% and 8%, 
respectively, and significantly higher than those observed in 
healthy controls (5.3% and 2%, respectively). 
The gestational diabetes mellitus (GDM) is the most 
commonly described pregnancy complication in women 
with PCOS with a threefold risk and an absolute risk of 
6%–15%.39–41 Two recent prospective studies confirmed an 
increased incidence of GDM of up to 14.7%43,44 and 22% in 
women with PCOS.45
Data on the risk of cesarean section, as well as those on 
the risk for adverse fetal outcomes, in women with PCOS are 
controversial,39–41 whereas no significant effect of PCOS on 
the risk for operative vaginal delivery has been detected.39,40 
Recently, the risk of preterm delivery was increased twofold 
and more in PCOS patients, even if confined to hyperan-
drogenic subjects.46 Neonates born to women with PCOS 
had a twofold increased risk for admission to the neonatal 
intensive care unit41 and their mortality was increased of 
threefold.39 Albeit the first published meta-analysis39 found 
no difference in risk of small-for-gestational age neonates, 
the most recent one found an almost twofold increased risk of 
small-for-gestational age and no risk of large-for-gestational 
age neonates.40 Two recent studies confirmed an increased 
risk of small-for-gestational age of four-47 and twofold and 
half43 in neonates of women with PCOS, whereas another 
study showed no effect of PCOS on the risk of small-for-
gestational age.46 On the other hand, an increased incidence 
of large-for-gestational age in PCOS patients was observed in 
a retrospective48 and in a prospective study.43 The incidence 
of macrosomia, however, was similar in PCOS women when 
compared to controls.39
On the basis of these considerations, recently, the recent 
Endocrine Society guidelines for the diagnosis and treat-
ment of PCOS16 declared that women with PCOS are at 
increased risk of pregnancy complications recommending 
preconceptual assessment of BMI, blood pressure, and oral 
glucose tolerance.16
Long-term complications
Cardiovascular risk
As reported by the main scientific societies,13,15,49 women 
with PCOS present an increased prevalence of classic risk 
factors for cardiovascular disease (CVD) such as hyperten-
sion, dyslipidemia, diabetes, and obesity and nonclassic risk 
factors such as C-reactive protein (CRP), homocysteine, and 
tumor necrosis factor-α.50 PCOS at any age is characterized 
by greater odds for elevated CVD risk markers and these 
elevated makers can occur without obesity but are magnified 
with obesity.13
In 2004, a worldwide case-control study of patients from 
52 countries was published, the INTERHEART study,51 that 
found nine potentially modifiable risk factors, accounted 
for over 94% of the population-attributable risk of a first 
myocardial infarction in women; the nine factors included 
smoking, hypertension, dyslipidemia, diabetes, visceral 
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Table 1 Summary of recommendations for the management of infertility in oligoanovulatory women with PCOS
Management of early complications
Lifestyle modification
(diet and physical activity)
First-line nonpharmacologic approach to treat obese/overweight 
oligoanovulatory PCOS patients
Clomiphene citrate First-line treatment of ovulatory infertility in women with PCOS
Letrozole Potential first-line treatment of ovulatory infertility but it is still off-label drug 
not recommended in clinical practice
Metformin Treatment of choice as clomiphene citrate sensitizing and as adjuvant therapy to 
prevent OHSS in PCOS women undergoing IvF cycle, but it is still off-label drug
Laparoscopic ovarian drilling Indicated in well-selected cases of oligoanovulatory PCOS  
women who need laparoscopic assessment of the pelvis
Gonadotropins Considered last treatment option in PCOS population  
for high costs, high risk of multiple pregnancies, and OHSS
Abbreviations: IvF, in vitro fertilization; OHSS, ovarian hyperstimulation syndrome; PCOS, polycystic ovary syndrome.
obesity, psychosocial factors, decreased consumption of 
fruits and vegetables, regular consumption of alcohol, and 
regular physical activity. The majority of these occur in the 
PCOS woman. It is estimated that the prevalence of each 
risk factor is approximately double for women with PCOS 
when compared with controls, while it is 1.5 times higher 
in BMI-matched studies beginning in adolescence and it is 
found in every decade.13
A study conducted in Brazil,52 regarding prevalence of 
hypertension in women with and without PCOS, revealed a 
twofold prevalence of the disorder in women with PCOS. The 
increased risk of hypertensive state seems to be explained by 
IR and hyperinsulinemia, typical of PCOS, that alter vascular 
smooth muscle cells causing hypertrophy of vascular muscle 
wall with reduced compliance and by the interference in 
the endothelium-dependent vasodilatation mechanisms.53 
Also high testosterone levels, but not sex hormone-binding 
globulin (SHBG) levels, increased the hypertension’s risk, 
even when adjusted for age, BMI, and other anthropometric 
and hormonal parameters.54 A Swedish study55 also showed 
that, even in the absence of a real hypertensive state, PCOS 
women presented a significantly higher daytime systolic 
blood pressure, mean arterial values of blood pressure, and 
an increased pulse rate, than healthy controls. This significant 
prehypertensive state remained even after adjusting for BMI, 
body fat distribution, and IR.55
Dyslipidemia is very common in PCOS patients,56 which 
is present in 70% of patients in the United States (US) with 
different patterns.57 Most often it is represented by hyper-
triglyceridemia and low high-density lipoprotein (HDL) 
cholesterol levels and small dense low-density lipoprotein 
(LDL) cholesterol particles (also called atherogenic lipopro-
tein phenotype),58,59 similar to that found in type-2 diabetes 
mellitus (T2DM) and typical for the states of IR,60 while the 
increased LDL cholesterol in PCOS is less dependent on 
body weight and may be partially related to the hyperandro-
genism.61 Higher non-HDL cholesterol, frequent in women 
with PCOS, reflects altered ApoB/A1 ratios, an important 
risk factor for CVD.61,62 Moreover, altered ApoB/ApoA ratios 
reflect also a more atherogenic lipoprotein lipid pattern in 
women with PCOS. The current evidences show that differ-
ent lipid patterns may be present in women with PCOS49 but 
the impact of dyslipidemia in different PCOS phenotypes is 
not known. Dyslipidemia may deteriorate with obesity but 
the influence of BMI on the severity of dyslipidemia is still 
controversial61 and may be influenced also by the origin of 
investigated PCOS women.63 In fact, differences between 
ethnic and geographical background are likely to depend on 
the combination of genetic, environmental, and hormonal 
factors.
Among the cardiovascular risk factors, T2DM repre-
sents one of the most important and PCOS is considered a 
major risk factor for developing impaired glucose tolerance 
(IGT) and T2DM, with a level A of evidence according to 
ESHRE/ASRM statement of the Third PCOS Consensus 
Workshop Group.13 PCOS is an independent risk factor for 
the development of T2DM and the progression of IR to glu-
cose intolerance and finally T2DM is variably. However, it 
is estimated that, in a third of those affected, T2DM occurs 
within 2–3 years64 and exceed 50% within 10 years.65 The 
negative association between glucose metabolism and PCOS 
is worsened by the presence of obesity; there is approximately 
three to four times more likeliness to develop diabetes than in 
women without PCOS or obesity but the association remains 
even in women with a BMI of less than 25 kg/m2 and in a 
BMI-matched study.66,10
More and more scientific evidences suggest a role of 
nonclassic CVD risk factors, related to a systemic inflamma-
tory state, in PCOS patients, such as CRP. CRP is commonly 
considered a vascular inflammatory marker that predicts the 
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Table 2 Summary of recommendations for clinical assessment and treatment of long-term PCOS complications
Management of long-term complications
Clinical assessment Therapeutic approaches
Metabolic risk Screening for impaired glucose tolerance and T2DM  
with 75 g OGTT in PCOS women with:
– age .40 years 
– BMI .30
– classic phenotype
– presence of achantosis nigricans
– personal and/or family history of T2DM
BMI and waist circumference at every visit:
– waist circumference .80 cm 
– abdominal obesity
Periodic reassessment with OGTT
Lifestyle change programs (hypocaloric diet and 
physical exercise) represent the first-line approach 
for obese PCOS women
Metformin use for prevention of diabetes in PCOS 
women with impaired glucose tolerance when lifestyle 
modification is not successful and/or as an adjuvant to 
general lifestyle modifications
Thiazolidinediones as alternative therapy in insulin-
resistant, obese PCOS patients who are intolerant 
or refractory to metformin, or with severe insulin 
resistance due to genetic disorder
Cardiovascular risk CvD risk assessment at any age with:
– blood pressure 
– lipid profle
– waist circumference
– BMI
– glucose profile
– cigarette smoking
– family history of early CvD
– evaluation for depression, anxiety, and quality-of-life
Categorize PCOS patients as “at risk”  
for CvD if present:
– obesity 
– hypertension
– dyslipidemia
– cigarette smoking
– subclinical vascular disease
– impaired glucose tolerance
– family history of premature CvD
Categorize PCOS patients as “at high risk”  
for CvD if present:
– metabolic syndrome
– T2DM
– vascular and/or renal disease
Periodic clinical reassessment
Lifestyle modification:
– diet
– physical exercise
– smoking cessation
Metformin use for prevention of T2DM in PCOS 
women with impaired glucose tolerance when lifestyle 
modification is not successful and/or as an adjuvant to 
general lifestyle modifications
Statins to lower LDL-C levels
Antihypertensive drugs
Oncological risk In presence of amenorrhoic patients or abnormal uterine 
bleeding, assessment for the presence of endometrial cancer with 
ultrasound and/or endometrial biopsy
Periodic progestogen withdrawal (at least four 
episodes per year) should be indicated in anovulatory 
PCOS women
Abbreviations: CvD, cardiovascular disease; OGTT, oral glucose tolerance test; PCOS, polycystic ovary syndrome; LDL-C, low-density lipoprotein cholesterol; BMI, body 
mass index; T2DM, type-2 diabetes mellitus.
development of CVD67 and T2DM.68 Studies reported higher 
CRP levels in women with PCOS,69 although the serum CRP 
levels seem to be more associated with obesity than with the 
presence of PCOS per se.70
Plasma homocysteine levels are widely accepted as an 
independent CVD risk factor and many different scientific 
papers have shown elevated plasma homocysteine levels in 
PCOS women,71,72 also independent of BMI,73 as a conse-
quence of the negative effects of IR and hyperinsulinemia 
on the homocysteine metabolism.
Other many biochemical inflammatory and throm-
botic markers of cardiovascular risk have been reported in 
excess in women with PCOS compared with non-PCOS 
controls,74,75 such as tumor necrosis factor-α, interleukin-6 
(IL-6), IL-18, IL-17, factor VIIc, tissue plasminogen activa-
tor (t-PA), fibrinogen, von Willebrand factor (vWF), plas-
minogen activator inhibitor-1 (PAI-1), thrombo-modulin, 
D-dimers, antithrombin III (ATIII), Sp-Selectin, endothelin-1 
(ET-1), asymmetric dimethylarginine (ADMA), intercel-
lular adhesion molecule-1 (ICAM-1), soluble vascular cell 
adhesion molecule-1 (sVCAM-1), serum advanced glyca-
tion end-products (AGEs), membrane receptor for AGEs 
(RAGE), malondialdehyde (MDA), nitric oxide (NO), and 
latency-associated peptides (LAPs).13
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Nevertheless, despite the higher prevalence of CVD 
risk markers in PCOS women than in healthy controls, the 
association of these markers with cardiovascular events 
remains unclear. Women with PCOS have more subclini-
cal vascular disease than healthy women but evidence for 
increased CVD morbidity and mortality in these women, 
based upon Rotterdam and/or NIH criteria, remains 
inconclusive.30,76,77
Retrospective studies show that typical features of PCOS, 
such as increased waist/hip ratio, hirsutism, or PCOM, are 
more commonly related to coronary artery disease in women 
undergoing coronary angiography.78,79 In asymptomatic 
women with PCOS, the presence of subclinical athero-
sclerosis has been determined using different invasive and 
more frequently noninvasive methods, as well as structural 
markers: endothelial function, carotid intima media thick-
ness (CIMT), and coronary artery calcification (CAC) score. 
Endothelial dysfunction, early sign of atherosclerosis, can 
be assessed by examining artery’s flow-mediated dilatation80 
and, in a recent meta-analysis,81 this parameter, measured 
at brachial artery, was found to be lower in women with 
PCOS compared to controls, even after controlling for age, 
BMI, and smoking. Endothelial dysfunction was shown to 
be associated with higher levels of androgens and with IR,82 
also observed at very early ages, with a trend of worsening 
from lean to overweight and obese PCOS women.83 Another 
assessment parameter of subclinical atherosclerosis is mea-
surement of CIMT. Increased CIMT correlates with a rise 
of CVD risk and a recent systematic review84 confirmed a 
thicker CIMT in women with PCOS compared to non-PCOS 
controls. Finally, CAC is a valid coronary atherosclerosis 
marker, used to assess the risk of myocardial infarction or 
sudden cardiac death;85 a recent systematic review86 of the 
studies showed that PCOS women have also been found 
to present a greater prevalence of CAC than unaffected 
women, and this was independent of age and BMI. These 
markers of subclinical atherosclerosis are correlated with 
age, components of metabolic syndrome, IR, and circulating 
androgen levels.87–89
Therefore, it could be assumed that the lifelong metabolic 
dysfunctions of PCOS are responsible for a worse cardio-
vascular profile and predispose for CVD with aging. Indeed, 
few studies aimed to investigate the true occurrence of CVD 
in PCOS women and most of them include women with a 
retrospective diagnosis of PCOS and/or studies not based on 
currently diagnostic accepted criteria. A 21-year controlled 
follow-up study,90 in a Swedish cohort of PCOS women, did 
not find an increased rate of myocardial infarction, stroke, 
or mortality, despite the higher prevalence of hypertension 
and dyslipidemia in that population. On the contrary, a recent 
meta-analysis91 found an increased incidence of cardiovascular 
events in women with PCOS, but did not distinguish between 
coronary heart disease and stroke. Finally, a more recent sys-
tematic review and meta-analysis92 showed that women with 
PCOS appear to be at increased risk of nonfatal stroke and 
possibly coronary heart disease, although the data synthesis 
did not provide evidence of increased risk in CVD in PCOS 
entirely independent of BMI.
To date, uncertainty exists to whether PCOS per se 
increases cardiovascular mortality and the impact of various 
lifestyle factors and of the different PCOS treatments, such 
as oral contraceptive pill, anti-androgens, insulin sensitizers, 
or laparoscopy ovarian diathermy on cardiovascular risk 
of these patients. A registry for patients with CVDs and a 
multisite longitudinal follow-up study or case-control study 
is urgently needed.13
Metabolic risk
Actually, obesity is considered a serious growing epidemic 
disorder in the world population, especially in the childhood 
and teenage years. Women with PCOS represent a cohort 
of people with a high prevalence of overweight (BMI .25 
kg/m2) and obesity (BMI .30 kg/m2) compared to healthy 
women, up to 61% of prevalence,93 with a typical central 
distribution of adipose tissue, although there is a wide vari-
ability in the estimates of obesity in PCOS women across 
different countries and ethnicities.13 In the Western countries, 
such as Australia, USA, and UK, the PCOS women have the 
highest prevalence of overweight and obesity,94,95 compared 
to Chinese PCOS women (only 20% has a BMI of 25 kg/m2 or 
greater).96 The causal role in the association between obesity 
and PCOS has yet to be determined but cultural, lifestyle, and 
ethnic factors take part in these conditions. Recent literature 
have found that greater adiposity was described in more 
severe reproductive phenotypes (characterized by hyperan-
drogenism associated with chronic anovulation),49 and lean 
women had milder reproductive phenotype compared with 
those who were overweight;97 so obesity can exacerbate the 
PCOS reproductive phenotypes. It also appears that obesity 
could have a bidirectional relationship with PCOS, as women 
with PCOS are more inclined to weight gain and excessive 
weight gain increases PCOS prevalence, unmasking a latent 
PCOS condition, but this yet remains to be clarified.98
Women with a diagnosis of PCOS are more likely to 
have upper body fat distribution, even in the absence of 
an obesity condition and independent of BMI levels. The 
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android fat distribution represents the most metabolic rel-
evant adipose tissue. In fact, the greatest health implications 
of PCOS are associated with excess weight and abdominal 
circumference99 because a greater visceral adiposity is 
associated with a greater IR,100,101 which is considered one 
of the most important metabolic pathogenetic key of the 
syndrome. Visceral obesity correlates with greater fasting 
insulin levels and greater insulin area under the curve.100,101 
Moreover, excess central adiposity reflects a worsened 
dyslipidemic profile, with higher triglyceride levels and low 
HDL cholesterol levels.102,103
IR, an essential etiological factor of PCOS, was tradition-
ally attributed primarily to obesity. Moreover, it showed the 
presence of an intrinsic IR in PCOS, independent of obesity, 
supported by some evidences, such as insulin-signaling 
abnormalities due to excessive serine phosphorylation on 
insulin receptor and to defects in post-receptor signaling 
molecules.104,105 The cellular and molecular mechanisms 
of IR in PCOS differ from those of IR that occurs in other 
metabolic disease, such as T2DM and obesity. However, the 
synergistic negative effect of PCOS and obesity on insulin 
action is well-recognized, as hepatic IR is present only in 
obese women with PCOS.105 Nevertheless, IR occurs also 
without obesity and its prevalence in lean women with PCOS 
is approximately of 75%.97
IR and associated hyperinsulinemia act by increasing 
androgen production by ovaries and decreasing hepatic 
SHBG production, resulting in free androgens excess.106 The 
amount of androgen excess worsens with obesity even if the 
association between body fat and hyperandrogenism seems 
to be indirect and, at least in part, mediated by IR and the 
associated hyperinsulinemia.107
Obesity and overweight increase the risk of developing 
T2DM in PCOS women, although, as previously reported, 
the PCOS represents an independent risk factor for T2DM.108 
In particular, the syndrome is considered a significant risk 
factor for development of DM both in later life and in young 
overweight or obese women with PCOS.13 In a recent system-
atic review and meta-analysis, the T2DM risk was increased 
fourfold compared with BMI-matched control groups while 
the odds ratio (OR) for IGT was 2.5.10 The likelihood of 
developing T2DM significantly increased as BMI, fasting 
glucose, and glucose area under the curve (AUC) at baseline 
increased and significantly decreased as SHBG levels at 
follow-up increased.109
The cardiometabolic profile of women with PCOS 
seems to depend on the different PCOS reproductive phe-
notypes, where women with hyperandrogenic PCOS (classic 
NIH-criteria PCOS) have a worse cardiometabolic profile 
and higher prevalence of CVD risk factors compared with 
women with non-hyperandrogenic PCOS.13,110 In particular, 
in women with hyperandrogenic PCOS, the prevalence 
of metabolic syndrome has been recently estimated at 
approximately 25.8%,110 in line with other prevalence’s valu-
ations according to the former 1992 NIH criteria.10 This rate 
of metabolic syndrome is significantly increased compared 
with that in reproductively healthy women of similar age and 
weight9,111 and compared with that in non-hyperandrogenic 
women with PCOS.110 This increased risk of metabolic 
syndrome may be explained by a severe IR associated with 
classic NIH-criteria PCOS and by hyperandrogenism, pos-
sible independent contributor to metabolic syndrome risk.105 
Moreover, women with PCOS, diagnosed according to the 
Rotterdam criteria (including other phenotypes than hyper-
androgenism and chronic anovulation), have much milder 
metabolic dysfunction or are even metabolically normal.112,113 
However, it was also found that similar cardiometabolic 
profiles are present where the different phenotypes present 
similar BMI or similar amount of visceral obesity or where 
the differences are corrected for adiposity; so it has been 
suggested that metabolic phenotype parallels reproductive 
phenotype but obesity can exacerbate the differences among 
the metabolic phenotypes.114
With regards of IGT and T2DM risk across the PCOS 
phenotype, a systematic review did not report differences in 
T2DM prevalence between the milder reproductive pheno-
types and the more severe phenotypes,113 and this issue has 
been later confirmed in a cross-sectional study where women 
with NIH and non-NIH PCOS have similar elevated T2DM 
risk, relative to controls, independent of age and adiposity, 
requiring a similar clinical screening and treatment for T2DM 
for both phenotypes of PCOS.115
Oncology risk
Since PCOS is considered as a lifelong multisystemic 
and multifaceted disorder, the reproductive and metabolic 
alterations characterizing the syndrome may be also associ-
ated with an increased risk of the development of cancers, 
such as the endometrial, ovarian, and breast cancer, which 
recognize potential hormonal and/or metabolic pathogenetic 
mechanisms. 
The first papers reporting an association between PCOS 
and endometrial cancer date back to the forties and fifties, but, 
to date, the lack of exhaustive evidence of the relationship 
between PCOS and gynecological malignancies can be mainly 
explained by the relative lack of studies compared with those 
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investigating cardiovascular morbidity in PCOS women116 
and by the small number of cases in each study. The potential 
mechanisms which could promote the onset of neoplastic dis-
eases in these women, particularly endometrial cancer, include 
the chronic anovulatory state, resulting in an unopposed 
estrogen action, associated with hyperandrogenism.117
At present, based on the most recent meta-analysis,118 
women with PCOS of all ages seem to be at an increased risk 
of endometrial cancer. In particular, the risk of endometrial 
cancer may be even higher in the premenopausal subgroup 
of women with PCOS, while overall the risk of ovarian and 
breast cancer was not significantly increased.118 These cur-
rent results are consistent with previous reviews published 
on cancer in PCOS116,119,120 but in contrast with a previous 
systematic review121 which found that women with PCOS 
were also at increased risk of ovarian cancer. That review, 
however, was lacking in meta-analytic analysis and included 
only one study about ovarian cancer in PCOS.
Unfortunately, as with studies of cardiovascular risk, the 
assessment of cancer risk in PCOS women is complicated 
by the presence of various potential confounding factors 
such as obesity, T2DM, inflammation, and metabolic 
syndrome, which are highly represented in PCOS popula-
tions. Obesity is a recognized risk factor for endometrial 
cancer and the authors of the most recent meta-analysis118 
acknowledge that the increased risk of this cancer could be 
attributed, at least in part, to increased prevalence of obesity 
in PCOS women. The same issue applies to T2DM, another 
possible confounding factor that is most representative in 
PCOS women and associated with an higher risk of endo-
metrial cancer, possibly secondary to hyperinsulinemia, 
hyperglycemia, and inflammation.122 Therefore, there is 
uncertainty as to whether increased endometrial cancer risk 
is due to different metabolic risk factors or PCOS itself, 
which is characterized by many metabolic and reproductive 
complications that could be responsible for an increased 
oncology risk on endometrium. Moreover, it is difficult 
to estimate the strength of this association because the 
PCOS diagnoses used in many of the studies are based on 
self-reports123,124 or on unusual criteria,125 and, mostly, the 
definition of PCOS has changed over time with limitations 
also in control groups.
Nonetheless, it is generally accepted that PCOS women 
with amenorrhea are at greater risk for endometrial hyper-
plasia and cancer;13 therefore, ESHRE/ASRM Consensus 
Workshop Group has established a proper endometrial sur-
veillance with ultrasound and/or biopsy to assess endometrial 
thickening in women which experience extended period of 
amenorrhea, based on clinical suspicion and presentation, 
and in these women periodic progestogen withdrawal is also 
recommended, at least four episodes per year.13
Agents that induce ovulation and improve the chance 
of pregnancy would also combat the unopposed estrogen 
and possibly lower the risk of endometrial hyperplasia and 
cancer.99 In the same way, metformin, an insulin-sensitizing 
agent, has been shown to exert a chemoprotective and anti-
proliferative effect on numerous cancers,126,127 and it has 
been suggested to have an antitumor effect on endometrial 
cancer.128 To date, however, there are scarce research data 
to support metformin use in PCOS women for endometrial 
cancer prevention in the clinical practice.129,130
There is limited and contradictory evidence regarding the 
risk of ovarian131 and breast cancer121 in women with PCOS; 
so currently, the ESHRE/ASRM consensus statement13 does 
not recommend routine surveillance strategy and/or clinical 
care to detect ovarian and breast cancer in women with PCOS. 
There is also insufficient evidence to evaluate any association 
of PCOS with vaginal, vulvar, and cervical cancer.
Other disorders
In addition to well-known cardiovascular and metabolic 
impairments, patients with PCOS present an increased risk 
for psychological disorders and reduced quality-of-life (QoL) 
compared to healthy women. 132–135 In a recent meta-analysis, it 
has been found that the prevalence rates of depression in PCOS 
range from 14% to 67%, with a fourfold greater odds of depres-
sive symptoms compared with age-matched control women.132 
Moreover, this greater risk is sustained also after subanalysis 
of BMI-matched subjects.132 A following systematic review of 
the literature showed an increased prevalence of generalized 
anxiety and an increase in mean anxiety scores in women with 
PCOS compared with control women.136 Limited data are pub-
lished about anxiety score in adolescents with PCOS, revealing 
a slight increase in anxiety in PCOS young women.137
The assessment of psychological symptoms and QoL 
can be performed with different validated disease-specific 
questionnaires or structured interviews, such as the Hospital 
Anxiety and Depression Scale, the Beck Anxiety Inventory, 
and the Beck Depression Inventory, that evaluate the fre-
quency of mental symptoms in anxiety and depression, 
respectively. A further questionnaire that addresses many 
areas including depression and anxiety is the Symptom 
Checklist 90. The Health-Related QoL has been investigated 
by generic questionnaires, such as the Short Form-36 (SF-36) 
questionnaire, the most frequently utilized instrument 
for many diseases besides PCOS, or by a more validated 
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questionnaire specific for PCOS subjects, the PCOS question-
naire, that involves analysis of emotions, hirsutism impact, 
weight, menstrual disorders, and infertility.138
In the literature, there is consistent evidence that patients 
with PCOS represent a group at high-risk for a lot of psycho-
logical disturbances and for reduced QoL. However, due to 
several biases and due to the heterogeneous nature of PCOS, 
with multiple phenotypes prevalence changing across the life 
span, it is difficult to establish from existing research as to 
what proportion of women with PCOS fall into the at-risk 
group.13 Moreover, the debate remains open about whether 
the increased prevalence of these psychological disorders 
is due to the PCOS itself or its features, such as obesity, 
hirsutism, irregular menses, and infertility. Relationship 
between obesity and QoL has been investigated, reporting 
an association between BMI and depression139 and poor 
QoL,134 with an improvement of depression and QoL score 
after weight loss.140,141 A recent meta-analysis136 is unable 
to perform a subanalysis of BMI-matched studies relative 
to association between anxiety symptoms and BMI, given 
the small numbers of studies included. Also the relationship 
between hyperandrogenism and anxiety symptoms need to 
be better evaluated because there are few studies evaluating 
this association and the available data are conflicting.136,142,143 
Another potential factor that may contribute to worse QoL 
and/or mood disorders is the infertility and the unfulfilled 
wish for a child, but it has been suggested that the diagnosis 
and or treatments for infertility may result in depressive or 
anxiety symptoms but not in an increased risk of clinically 
significant psychological disorders.144
The high prevalence of depression and anxiety in these 
patients led many authors15,136,139 to include a psychological 
assessment not only in the initial evaluation of women with 
PCOS but also in their follow-up. Moreover, the ESHRE/
ASRM Consensus Group13 considers as premature a psy-
chological screening to all women with PCOS. Neverthe-
less, more research should be addressed to the evaluation of 
the validity of the existing psychological questionnaire as 
screening tools and to the development of new appropriate 
screening instruments and interventions.13
Management of early complications
Several treatments for ovulatory infertility related to PCOS 
were proposed over the years. Table 1 summarizes the recom-
mendations for the management of infertility in women with 
PCOS. On the other hand, only preliminary data are to date 
available regarding the management of obstetric complica-
tions in women with PCOS.
Lifestyle modifications
Obesity was closely related to IR; for this reason, weight 
loss represented a fundamental preliminary approach in the 
treatment of obese/overweight PCOS women. In fact, weight 
loss resulted in the restoration of spontaneous ovulation and 
higher fertility rate.145 An aggressive approach to reduce 
weight, including pharmacological strategies and the use 
of contraception and high-dose folic acid was proposed for 
obese women before planning a pregnancy.145
However, lifestyle modification programs are related 
to a low compliance and a high dropout rate. To overcome 
this problem, the feasibility and the efficacy of a structured 
exercise training program was evaluated in obese anovulatory 
PCOS patients.146 The structured exercise training resulted in 
a higher menses frequency and the ovulation in comparison 
with diet, even if the cumulative pregnancy rate was similar 
between two approaches.146 Successively, lifestyle modifi-
cations resulted more efficacious than clomiphene cictrate 
(CC) and metformin in terms of pregnancy rate, resulting 
in 12.2%, 14.4%, 14.8% and 20% of pregnancies after CC, 
metformin, CC plus metformin, and lifestyle modification, 
respectively.147
Recent guidelines suggested the use of exercise therapy 
in the management of overweight and obesity in PCOS.16 
However, the effect of the weight loss on pregnancy outcome 
in women with PCOS has been not adequately assessed. 
Moreover, although confirmatory evidence-based data on 
the issue are lacking, we also consider the lifestyle modifica-
tions, including hypocaloric diet and physical activity, the 
first-line approaches for the prevention of early complications 
of PCOS in case of overweight and obesity.
Clomiphene citrate
Available guidelines recommended CC as the first-line treat-
ment of anovulatory infertility in women with PCOS.16 CC is 
an estrogen modulator, efficacious, simple to administer and 
to manage, safe and cheap. Specifically, CC was effective 
in increasing pregnancy rate compared to placebo (OR 5.8, 
95% CI 1.6–21.5).148
According to the standard protocol, CC is administered 
for 5 days from second or third day of the menstrual cycle, 
starting from 50 mg/day and increasing up to 250 mg/day. 
“Managed care” studies showed that the most effective dos-
age is 100–150 mg/day and over 75% of ovulations occur 
already within a dosage of 100 mg/day.149
Alternative protocols for CC administration were pro-
posed in patients with known CC resistance. Extended CC 
regimen resulted in higher ovulation and pregnancy rates 
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in comparison with gonadotropins ovulation induction, 
suggesting that in CC-resistant PCOS patients a further 
period of CC administration might be preferable.149
Further protocols for CC administration, such as luteal 
phase and stair-step regimens, were recently proposed.149 
The administration of 100 mg of CC daily in the luteal phase 
resulted in improved ovulation and pregnancy rates, although 
in any case the significance was obtained, whereas the total 
number of follicles during stimulation was significantly 
higher.149 Stair-step protocol, consisting in 50 mg CC for 
5 days followed by weekly increasing dose of 50 mg CC in 
case of absent ovarian response, up to 150 mg daily, resulted 
less time-consuming and more efficacious in terms of ovula-
tion rate in CC-resistant women.
In our practice, CC (at a dosage of 100 mg/day, and for 
not more than six cycles) remains a valid therapy for inducing 
ovulation in infertile PCOS patients.
Aromatase inhibitors
Aromatase inhibitors (AIs), such as estrogen modulators, 
were approved by the Food and Drug Administration as first-
line adjuvant therapies for estrogen-receptor–positive breast 
cancer.150 Several data150 evaluated the efficacy of AIs, and 
in particular of letrozole, as first-line therapy for inducing 
ovulation in infertile patients affected by PCOS. Letrozole 
was usually administered at a dose of 2.5 mg/day, for 5 days 
from the third to the seventh day of the menstrual cycle.
More recently, a meta-analysis of RCTs showed that 
letrozole is related to significantly higher live-birth rates than 
CC (OR 1.64, 95% CI 1.32–2.04).151 Furthermore, the quality 
of the evidence was considered low due to the poor study 
transparency in reporting methods and in consideration of 
the more favorable results in the trials reporting live birth as 
primary end point. Excellent results of AIs in terms of cumu-
lative live-birth rate and singleton pregnancy was reported 
in the largest multicenter randomized double-blind parallel 
controlled trial (Pregnancy in PCOS trial II, PPCOS II) 
comparing letrozole to CC.152
To date, letrozole remains an off-label drug.153 Studies 
are needed to validate the efficacy/safety of AIs over CC in 
further settings and to clarify its role in well-codified strate-
gies and algorithms for ovulation induction in PCOS.150 Thus, 
the use of AIs in clinical and nonexperimental settings should 
be probably avoided.
Metformin
Metformin belongs to insulin-sensitizing drugs commonly 
used in treating T2DM. Because IR is a common condition in 
PCOS women, metformin was introduced in clinical practice 
in the treatment of these patients.154
Metformin is available in two formulations: immediate- 
and extended-release, which are administered orally. Even 
if no dose-finding study is available, metformin administra-
tion at incremental doses from 500 to 2,500 mg/day was 
proposed to treat women with PCOS.154 Several systemic and 
local effects were demonstrated to explain the reproductive 
benefits due to metformin administration.154
In practice, metformin seemed to restore the ovulatory 
function after almost 3 months of treatment; thus it could 
be recommended in PCOS patients who absolutely wish 
to avoid multiple gestations and/or in patients who do not 
tolerate CC and/or in those who do not have an imminent 
reproductive need.154
Metformin seemed to have no benefit in terms of preg-
nancy and live-birth rates in comparison with CC, even 
if it was effective in restoring ovulation in CC-resistant 
patients.154 Moreover, metformin addition to gonadotropins-
controlled ovarian stimulation for IVF and non-IVF cycles 
modulated the ovarian response to gonadotropins and 
reduced the risk for ovarian hyperstimulation syndrome 
(OHSS). Thus, its use could be planned for patients at high 
risk for OHSS.16,154 Finally, preliminary data suggested that 
metformin decreased the frequency of both early pregnancy 
loss and GDM,38 without increasing the risk for major birth 
defects in women with PCOS.155
To the present, metformin was still considered a drug of 
off-label use in women with PCOS. Guidelines16 discouraged 
the use of metformin as a first-line treatment for prevention 
of pregnancy complications, or for the treatment of obesity. 
No specific indication was given considering the potential 
effects of metformin pretreatment before starting subsequent 
standard infertility treatments. On the other hand, the use of 
metformin was suggested as an adjuvant therapy for infertility 
to prevent OHSS in women with PCOS undergoing IVF.156
On the basis of literature data and on our experience, met-
formin (at a dosage of 1,700–2,000 mg/day, and for at least three 
cycles) should be used in selected cases of oligoanovulatory 
PCOS patients who wish to avoid multiple gestation and/or 
in patients who do not tolerate CC, are CC-resistant and/or 
in those who do not have an imminent reproductive need 
and/or in those undergoing IVF and at high-risk for OHSS 
(ie, PCOM phenotype). 
Laparoscopic ovarian drilling
Laparoscopic ovarian drilling (LOD) is currently indicated 
as a safe, efficacious, and cost-effective alternative to 
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gonadotropins for ovulation induction in infertile women 
with PCOS and who are CC-resistant.157 Advantages of LOD 
consisted in the absence of risk for OHSS and/or multiple 
pregnancies.
Since LOD improves ovarian responsiveness to CC, it 
may be considered after CC failure before proceeding to the 
IVF. Despite its advantages, LOD should be considered a 
non-first-line therapy in PCOS due to the availability of valid, 
cheaper, and less invasive alternatives.157 Rather, it should be 
reserved to well-selected cases, ie, anovulatory CC-resistant 
PCOS women who are young and/or not compliant to the 
alternative treatments and/or needing laparoscopic assess-
ment of the pelvis.
Gonadotropins
Gonadotropins are the cornerstone of the ovulation induc-
tion therapy in ovulatory infertility. However, gonadotropin 
administration was related to high costs, need for close 
monitoring, and high risk of multiple pregnancies and OHSS, 
particularly increased in PCOS subjects. For this reason, 
gonadotropins are often relegated as last treatment option 
in that population.
Notwithstanding, gonadotropins are used in ovulation 
induction protocols for many years, two main questions are 
still unanswered. The first regards the type of gonadotropins 
to use, while the last concerns the gonadotropin protocol to 
follow.
No difference between urinary (u) and recombinant 
(r) follicular-stimulating hormone (u/rFSH) was observed 
in safety, ovulation rate, pregnancy, abortion, multiple 
pregnancy, and OHSS.158 Regarding the gonadotropins 
dose and regimen, efforts to reduce the frequency of OHSS 
have resulted in the development of low-dose protocols, 
which used a starting dose of 37.5 or 75 IU/day instead the 
original conventional protocol.159 No difference was shown 
between the traditional “step-down” and the “low-dose 
step-up” regimen.159 On the contrary, the “low-dose” rFSH 
regimen was demonstrated to be more effective and well-
tolerated than uFSH in ovulation induction of CC-resistant 
PCOS patients.159 Finally, guidelines159 recommended 
a starting dose of gonadotropins of 37.5–50 IU/day, 
with small FSH dose increment of 50% of the initial or 
previous FSH dose in order to reduce the excessive ovar-
ian stimulation.
In our practice, in PCOS patients, we use gonadotropins 
at low-dose, step-up protocol starting with a gonadotropin 
dose of 37.5 IU daily for 7 days; we usually increase the 
dose of 50% every week up to a total of 30 days. In case of 
no ovarian response, the maximal dosage achieved will be 
employed for the subsequent cycle(s).
Management of the long-term 
complications
The long-term risks observed in women with PCOS are not 
the same in all PCOS patients but they vary according to 
different phenotypes and results were negatively affected 
by obesity and lifestyle factors. When Rotterdam criteria are 
applied, almost uniformly accepted by the main scientific 
societies,13,15,16 the prevalence of PCOS in the population 
increases to over 20%,160 with a large majority, approximately 
75%, of referred PCOS women having “classic” PCOS 
(according to NIH criteria) and the remaining 25% equally 
divided between ovulatory and non-hyperandrogenic PCOS 
phenotypes.161 Several studies13,162 suggest that women with 
PCOS, based on the classic-NIH criteria, exhibit a more 
detrimental metabolic and cardiovascular profile compared to 
milder phenotypes. In line with these considerations, the main 
scientific societies dealing with PCOS,13,15,16,49 have recently 
proposed guidelines and consensus statements, suggesting a 
correct diagnostic approach to PCOS patients and an effort 
to properly identify the phenotype of each patient, with the 
aim to target specific treatments and to prevent these severe 
long-term risks.
In relation to metabolic risks, the ESHRE/ASRM-
Sponsored PCOS Consensus Workshops Group13 and the 
AE-PCOS Society49 recommend performing an oral glucose 
tolerance test (OGTT), consisting of a fasting and a 2-hour glu-
cose level using a 75 g oral glucose load, as screening for IGT 
and T2DM in PCOS women with classic-phenotype (hyper-
androgenism and anovulation), obesity (BMI .30 kg/m2), 
acanthosis nigricans which represents a pathognomonic sign 
of IR, and a personal history of GDM or a family history of 
T2DM. The AE-PCOS Society49 recommends OGTT also in 
lean PCOS women with advanced age (.40 years). The Endo-
crine Society and the European Society of Endocrinology16 
broaden the OGTT recommendation to all adolescents 
and adult women with PCOS because considering all of 
them at high risk of IGT and T2DM. The major scientific 
societies13,15,16,49 converge to not use hemoglobin A1c as 
screening tool because it is not a sensitive methods of screen-
ing for T2DM in situations of risk, such as PCOS,163,164 and 
limited studies have shown poor sensitivity of hemoglobin 
A1c for detecting IGT,165 an important risk factor for CVD.166 
Instead, there is no agreement about the interval for peri-
odic follow-up of these patients. This interval varies from 
2 years, or annually in those with IGT, according to AE-PCOS 
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Society statement,49 to 3–5 years based on Endocrine Society 
guideline;16 both agree to anticipate the interval in presence 
of risk factors, such as central adiposity, weight gain, and/or 
symptoms of diabetes develop.
In consideration of the increasing prevalence of obesity, 
particularly abdominal, and the important bearing on the 
phenotype of PCOS, it is recommended that BMI and waist 
circumference be determined at every visit,167 considering 
the presence of abdominal obesity in European women with 
a waist circumference of at least 80 cm.167
Regarding the cardiovascular risk in PCOS women, AE-
PCOS Society49 proposed, according to CVD risk classifica-
tion provided by American Heart Association,168 to categorize 
the PCOS-related CVD risk as: “at risk” for PCOS women 
with any following risk factors: obesity, cigarette smoking, 
hypertension, dyslipidemia, subclinical vascular disease, 
IGT, and/or family history of premature CVD (,55 years 
of age in male relative, ,65 years of age in female relative); 
and “at high risk” for PCOS women with metabolic syndrome 
and/or T2DM and/or overt vascular or renal disease.
There is an overall consensus about the increased cardio-
vascular risk in the PCOS patients, due to relevant metabolic 
dysfunctions. Therefore, all societes13,15,16,49 agree to recom-
mend a CVD risk assessment at any age, for blood pressure, 
complete lipid profile (including total, LDL, HDL, non-HDL 
cholesterol, and triglycerides), waist circumference, BMI, 
glucose profile, cigarette smoking, and a family history of 
early CVD. Moreover, depression and anxiety disorders are 
recognized as risk factors for CVD and they are common 
in PCOS women; so it is suggested that PCOS patients 
be assessed also for depression, anxiety, and QoL.15,16,49 
Because cardiovascular risk increases with age and it can 
be exacerbated by obesity and worsened by environmental 
insults, periodic reassessment for CVD risk is suggested but 
there is no agreement how often the CVD risk assessment 
should be repeated.
Finally, there is no agreement on the optimal method, 
whether ultrasound or endometrial biopsy, and timing of 
screening for endometrial cancer. Despite the established 
increased risk of endometrial cancer in PCOS women,118 
there are no data supporting routine ultrasound screening for 
endometrial thickness169 or routine endometrial biopsy170 in 
asymptomatic women. In line with American Cancer Soci-
ety Guidelines,171 the decision to assess for the presence of 
endometrial cancer should be based essentially on the pres-
ence of abnormal uterine bleeding or spotting. Other relevant 
decision factors are amenorrhea length, women’s age, and 
the ultrasound appearance of endometrium.13
Lifestyle change, including hypocaloric diet and physical 
exercise, is considered a cornerstone of the management of 
women with PCOS presenting with obesity, particularly the 
abdominal phenotype;15 so it is generally recommended as a 
first-line approach for obese PCOS women.13,15,16,49 However, 
there are few randomized controlled trials that support this 
recommendation. A Cochrane review172 about the lifestyle’s 
impact on PCOS women supports the benefits of lifestyle 
treatment in PCOS patients. In particular, when compared 
to minimal treatment (consisting of unstructured minimal 
dietary, exercise or behavioral advice), lifestyle intervention 
is able to improve anthropometric markers, such as weight 
and fat distribution, total testosterone levels, Ferriman–
Gallwey score, fasting, and OGTT insulin concentrations. 
However, it does not reduce free androgen index that is 
considered a real marker of hyperandrogenism; it neither 
shows effects on OGTT glucose, fasting glucose levels, or 
lipid profile, compared to controls.172
The dietary advices represent the main components of the 
lifestyle changes, in particular for obese women, but the dietary 
composition seems to influence the metabolic improvements 
of the PCOS women to a lesser extent when compared to the 
weight loss.173 In fact, a 5%–10% weight loss is considered 
clinically significant and able to reduce IGT and metabolic 
syndrome prevalence in general population.174 However, 
no evidence-based data are actually available in order to 
suggest a specific hypocaloric diet.175 New data, obtained 
in populations unselected for PCOS, seem to suggest a role 
for the Mediterranean diet for cardiometabolic prevention in 
PCOS patients, both obese and nonobese.175 A recent review 
and meta-analysis176 confirms that physical exercise and/or 
hypocaloric dieting are efficacious in overweight/obese 
women with PCOS through a significant, but small, effect 
on glucose and insulin blood levels. This review also found 
a direct correlation between the weight reduction and the 
improvement in metabolic parameters that could be attributed 
to decreased IR or to other factors, not allowing the evalua-
tion of the independent effect of lifestyle modifications after 
accounting for weight loss.176 Also, the best type and optimal 
frequency of physical exercise required for treating PCOS has 
not been yet established.177 Other key issue, lifestyle treat-
ment needs to be maintained long term for improvement of 
the metabolic PCOS outcomes but in literature exist only few 
randomized studies beyond 6 months of follow-up.
Currently, despite the limitations of the existing evi-
dences, lifestyle changes, aiming at sustained weight loss, 
should be recommended as first-line treatment in overweight/
obese PCOS women, given the limited health risks, the low 
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costs, and the modest benefits with other interventions.176 
Future prospective requires longer and larger trials to draw 
stronger conclusions about the effects of lifestyle modifica-
tions on PCOS outcomes, to determine optimal weight loss 
for all these clinical improvements, and to establish the pos-
sible effects also in lean PCOS patients.
Since it is difficult to maintain a reduced weight for a long 
term with a correct lifestyle program, bariatric surgery in PCOS 
obese patients has been proposed as an effective tool for weight 
loss,178 and recent Australian guidelines on PCOS managment179 
suggest lowering the BMI threshold to propose bariatric 
surgery, considering the great impact of obesity to metabolic 
impairment of these PCOS women. Hence, bariatric surgery 
could be considered as part of the treatment in obese PCOS 
patients15 but additional researches about the role of this surgery 
on the different aspects of the syndrome is required.13
From a pharmacological standpoint, considering the 
metabolic and hormonal relevance of IR and associated 
compensatory hyperinsulinemia, common features of the 
PCOS women, the treatment choices have been expanded to 
insulin-sensitizing agents, in particular, metformin.154
The effects of metformin on obese PCOS patients are 
known since the first study of Velazquez et al.180 Since then, 
a large number of studies has been published to investigate 
the rationale of metformin use in PCOS women. The women 
with PCOS, both obese or nonobese, are characterized by 
an IR and hyperinsulinemia more relevant compared to that 
of age- and weight-matched control’s women, suggesting 
a tendency toward IR which is independent of obesity.181
 
Accordingly, when an impaired insulin sensitivity is 
present, the use of metformin might be suggested.154,182 A 
Cochrane review183 showed that metformin reduces serum 
testosterone levels and fasting insulin concentrations to a 
significant extent only among nonobese women. However, 
metformin is unlikely to replace combined oral contracep-
tives as first-line therapy for hirsutism, as shown in another 
Cochrane review.184 Moreover, metformin is not of benefit in 
improving weight loss, insulin sensitivity, or lipid profiles; 
hence a long-term prophylactic treatment with metformin 
is unlikely to prevent progression to diabetes.183 In line with 
these considerations, the main Societies13,15,16 agree to con-
sidered metformin for prevention of diabetes in women with 
PCOS and IGT when lifestyle modification is not successful 
and/or as an adjuvant to general lifestyle modifications that 
remains the first-line therapy for PCOS women at increased 
metabolic risk.
Among the insulin-sensitizing agents, the thiazolidin-
ediones (TZDs), including pioglitazone and rosiglitazone, 
are other insulin-sensitizing drugs that have been more 
recently studied in women with PCOS. They have been 
shown efficacy in improving insulin sensitivity and IGT, as 
well as ovulation rate and menstrual ciclicity,185,186 but they 
are not considered as a first-line choice for PCOS women 
because there is not sufficient evidence to support their meta-
bolic superiority over metformin.185 In addition, TZDs are 
classified by FDA as category C (potential teratogenic risk 
in fertile women), they should not be prescribed to patients 
with any liver disease or liver biochemical abnormalities, and 
there is concern about possible adverse cardiovascular events 
associated with rosiglitazone use.187 Therefore, TZDs may 
be considered as an alternative therapy in insulin-resistant, 
obese PCOS patients who are intolerant or refractory to 
metformin,15 or in PCOS women with severe IR due to 
genetic disorder.188
At present, in overweight/obese PCOS women, we advice 
lifestyle changes (consisting of Mediterranean diet and physi-
cal activity) as preliminary approach, at any age, with the aim 
of weight loss. We suggest the association with metformin 
in obese/overweight PCOS patients when lifestyle program 
alone is not enough to obtain metabolic improvements and 
we proposed metformin use in lean PCOS patients with 
impaired insulin sensitivity.
Conclusion
Overall, women with PCOS show an increased risk of obstet-
ric, cardiovascular, metabolic, and psychological complica-
tions compared to non-PCOS women. These risks do not have 
the same entity in all PCOS subjects and can change during 
life. This variability seems closely related to PCOS pheno-
types. However, the pathogenetic mechanism which links 
PCOS to the high rate of early-term and long-term complica-
tions is not fully known. The same PCOS-related hormonal 
and metabolic features, such as hyperandrogenism, IR and 
related hyperinsulinemia, and visceral obesity, play a crucial 
role in increasing these risks but the exact mechanisms with 
which they act have not yet been completely elucidated.
PCOS is influenced by the race since ethnic differences 
occur in both the metabolic phenotype social models of 
behavior, likely contributing to the differing expressions of 
PCOS, with distinct impact on QoL of these women, as well 
as on the long-term consequences.
Despite the aging-related increase in IR and abdominal 
obesity in all women and the worsening of the cardiometa-
bolic profile after the menopause, women with PCOS seem to 
improve or to reach a plateau in some metabolic risk factors 
during menopausal transition (eg, in LDL cholesterol levels189 
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or glucose tolerance64). At the moment, well-designed lon-
gitudinal follow-up studies comparing PCOS subjects with 
healthy women from early reproductive age into menopause 
are lacking, and those available provide unclear and conflict-
ing findings. Indeed, the transition of women with PCOS into 
menopause and the potential PCOS phenotypes in postmeno-
pause are poorly understood, even if an improved menstrual 
cyclicity and a substantial decrease in testosterone levels in 
PCOS women are observed.
In the light of these considerations, all women with a 
diagnosis of PCOS should be screened for the presence of 
obstetric, cardiovascular, and metabolic risk factors but it 
is equally important to consider the heterogeneity of the 
syndrome, due to age of patients and to several hormonal, 
reproductive, and ethnic features. Unfortunately, there are 
not yet available specific diagnostic criteria based on differ-
ent age groups or based on specific ethnic origin. Further 
research is needed to improve diagnostic process with aim 
to select specific treatment, customizing the therapy and the 
lifestyle modifications.
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